REPORTS

Let’s Pullulate and Expand Your Business

Age Related Macular Degeneration Biologic Drug Market - Global Professional Analysis and Forecast to 2026

Nov 06, 2019  |  217 PAGES  |  REPORT CODE: CMM229994
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Age Related Macular Degeneration Biologic Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.4% during the forecast period.

This report presents the market size and development trends by detailing the Age Related Macular Degeneration Biologic Drug market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Age Related Macular Degeneration Biologic Drug market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Age Related Macular Degeneration Biologic Drug industry and will help you to build a panoramic view of the industrial development.

Age Related Macular Degeneration Biologic Drug Market, By Type:

  • Ranibizumab

  • Bevacizumab

  • Aflibercept

Age Related Macular Degeneration Biologic Drug Market, By Application:

  • Outpatient Surgery Center

  • Eye Clinic

  • Hospital

Some of the leading players are as follows:

  • Genentech

  • Allergan

  • Regeneron

  • Alimera Sciences

  • Eli Lilly

  • Merck

  • Ophthotech Corporation

  • Novartis

  • Bayer

  • Acucela

  • Valeant

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Age Related Macular Degeneration Biologic Drug Market: Technology Type Analysis

  • 4.1 Age Related Macular Degeneration Biologic Drug Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Age Related Macular Degeneration Biologic Drug Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Ranibizumab

    • 4.3.2 Bevacizumab

    • 4.3.3 Aflibercept

5 Age Related Macular Degeneration Biologic Drug Market: Product Analysis

  • 5.1 Age Related Macular Degeneration Biologic Drug Product Market Share Analysis, 2018 & 2026

  • 5.2 Age Related Macular Degeneration Biologic Drug Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Age Related Macular Degeneration Biologic Drug Market: Application Analysis

  • 6.1 Age Related Macular Degeneration Biologic Drug Application Market Share Analysis, 2018 & 2026

  • 6.2 Age Related Macular Degeneration Biologic Drug Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Outpatient Surgery Center

    • 6.3.2 Eye Clinic

    • 6.3.3 Hospital

7 Age Related Macular Degeneration Biologic Drug Market: Regional Analysis

  • 7.1 Age Related Macular Degeneration Biologic Drug Regional Market Share Analysis, 2018 & 2026

  • 7.2 Age Related Macular Degeneration Biologic Drug Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Genentech

    • 9.1.1 Genentech Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Allergan

    • 9.2.1 Allergan Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Regeneron

    • 9.3.1 Regeneron Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Alimera Sciences

    • 9.4.1 Alimera Sciences Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Eli Lilly

    • 9.5.1 Eli Lilly Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Merck

    • 9.6.1 Merck Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Ophthotech Corporation

    • 9.7.1 Ophthotech Corporation Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Novartis

    • 9.8.1 Novartis Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Bayer

    • 9.9.1 Bayer Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Acucela

    • 9.10.1 Acucela Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Valeant

    • 9.11.1 Valeant Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

 

The List of Tables and Figures (Totals 113 Figures and 142 Tables)

  • Figure Ranibizumab Age Related Macular Degeneration Biologic Drug market, 2015 - 2026 (USD Million)

  • Figure Bevacizumab Age Related Macular Degeneration Biologic Drug market, 2015 - 2026 (USD Million)

  • Figure Aflibercept Age Related Macular Degeneration Biologic Drug market, 2015 - 2026 (USD Million)

  • Figure Outpatient Surgery Center market, 2015 - 2026 (USD Million)

  • Figure Eye Clinic market, 2015 - 2026 (USD Million)

  • Figure Hospital market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Age Related Macular Degeneration Biologic Drug market, by country, 2015 - 2026 (USD Million)

  • Table North America Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table North America Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table North America Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table Canada Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table Canada Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Europe Age Related Macular Degeneration Biologic Drug market, by country, 2015 - 2026 (USD Million)

  • Table Europe Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table Europe Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table Europe Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table Germany Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table Germany Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table France Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table France Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table Italy Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table Italy Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table Spain Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table Spain Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Age Related Macular Degeneration Biologic Drug market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table China Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table China Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table Japan Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table Japan Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table India Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table India Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Age Related Macular Degeneration Biologic Drug market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table MEA Age Related Macular Degeneration Biologic Drug market, by country, 2015 - 2026 (USD Million)

  • Table MEA Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table MEA Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table MEA Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Age Related Macular Degeneration Biologic Drug market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Age Related Macular Degeneration Biologic Drug market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Age Related Macular Degeneration Biologic Drug market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Genentech Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Allergan Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Regeneron Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Alimera Sciences Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Merck Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Ophthotech Corporation Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novartis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bayer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Acucela Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Valeant Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top